Miguel‐Ángel Berciano‐Guerrero

Statistics

Publications

Citations

232

H-Index

Active since

2017

Affiliations

Instituto de Investigación Biomédica de Málaga(Current)

Hospital General Universitario De Valencia

Hospital Universitario Miguel Servet

Instituto Oncológico Dr. Rosell

Hospital Universitario Virgen Macarena

Miguel‐Ángel Berciano‐Guerrero is an author at Instituto de Investigación Biomédica de Málaga specializing in oncology, immunotherapy, and cancer immunotherapy.

ORCID

Publications per year

2017–2024

Publications

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen et al. · Clinical Cancer Research · 2023 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

María González‐Cao, Clara Mayo de las Casas, Juana Oramás et al. · Nature Communications · 2021 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Philip R. Clingan, Rahul Ladwa, Daniel Brungs et al. · Journal for ImmunoTherapy of Cancer · 2023 · 44 citations · Full text

Pharmacy, Oncology, Pharmacology +17

High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade

Juan Luis Onieva, Qingyang Xiao, Miguel‐Ángel Berciano‐Guerrero et al. · International Journal of Molecular Sciences · 2022 · 30 citations · Full text

Medicine, Immunology, Oncology +17

Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice

Elísabeth Pérez-Ruiz, Jerónimo Jiménez-Castro, Miguel‐Ángel Berciano‐Guerrero et al. · Clinical & Translational Oncology · 2020 · 19 citations

Life Sciences, Immunology, Oncology +16

1–5 of 8